Overview
Diabetic retinopathy (DR) is the most common cause of preventable blindness among adults in the United States and worldwide. It arises when chronically elevated blood glucose damages the tiny blood vessels (microvasculature) that supply the light‑sensing layer of the eye, the retina. Early changes include thickening of the basement membrane, loss of pericytes, and increased vascular permeability, which manifest clinically as microaneurysms, hemorrhages, and retinal edema. As the disease advances, abnormal new vessels (neovascularization) proliferate, often leading to vitreous hemorrhage, tractional retinal detachment, and irreversible vision loss.Screening is essential because patients may be asymptomatic for years; up to 40 % of individuals with diabetes have some degree of retinopathy at diagnosis. Management combines tight systemic control of blood glucose, blood pressure, and lipid levels with ocular interventions such as laser photocoagulation, intravitreal anti‑vascular endothelial growth factor (anti‑VEGF) injections, and vitrectomy surgery. Early detection and treatment can preserve vision in the overwhelming majority of cases.
When to seek professional care: Anyone with type 1 or type 2 diabetes should have a dilated retinal exam at diagnosis (type 1) or at the time of diagnosis (type 2) and at least annually thereafter. Sudden visual changes, floaters, or flashes of light require urgent ophthalmologic evaluation.
History/Background
The link between diabetes and eye disease was noted as early as the 19th century, but the term “diabetic retinopathy” entered the medical literature in the 1930s. In 1948, Dr. C. S. H. Miller described the characteristic microaneurysms and hemorrhages that define the condition. The 1960s saw the first systematic epidemiologic studies, establishing DR as a leading cause of blindness in industrialized nations. The introduction of fluorescein angiography in the 1970s allowed clinicians to visualize retinal vascular leakage, dramatically improving diagnostic accuracy.A watershed moment arrived in 1985 when the Early Treatment Diabetic Retinopathy Study (ETDRS) demonstrated that timely laser photocoagulation reduced the risk of severe visual loss by 50 % in patients with clinically significant macular edema. The 2000s brought anti‑VEGF therapy (e.g., ranibizumab, aflibercept), which now serves as first‑line treatment for proliferative DR and diabetic macular edema, shifting the therapeutic paradigm from destructive laser to pharmacologic neovascular inhibition.
Key Information
- Epidemiology: Approximately 30‑40 % of people with diabetes develop some retinopathy after 10 years; prevalence rises to >80 % after 20 years of disease. - Classification: DR is staged as mild non‑proliferative, moderate non‑proliferative, severe non‑proliferative, and proliferative; diabetic macular edema (DME) is a separate, vision‑threatening entity. - Risk factors: Poor glycemic control (HbA1c > 7 %), hypertension, hyperlipidemia, pregnancy, and longer diabetes duration increase risk. - Screening guidelines: The American Diabetes Association recommends a baseline dilated eye exam at diagnosis for type 2 diabetes and within five years of onset for type 1, followed by annual exams; more frequent visits are advised for existing retinopathy. - Diagnostic tools: Dilated fundus examination, optical coherence tomography (OCT) for macular thickness, fluorescein angiography for vascular leakage, and ultra‑widefield imaging for peripheral lesions. - Treatment modalities: - Laser photocoagulation (focal for DME, pan‑retinal for proliferative DR). - Intravitreal anti‑VEGF agents (ranibizumab, aflibercept, bevacizumab). - Corticosteroid implants for refractory DME. - Vitrectomy for non‑resolving vitreous hemorrhage or tractional retinal detachment. - Prognosis: With modern therapy, >90 % of eyes retain functional vision; however, untreated proliferative DR carries a 50 % risk of severe vision loss within five years.Significance
Diabetic retinopathy exemplifies how systemic metabolic disease can produce localized, organ‑specific damage with profound public‑health implications. Its prevalence mirrors the global rise in diabetes, making DR a leading cause of blindness in low‑ and middle‑income countries where screening infrastructure may be limited. The condition has driven advances in imaging (OCT, ultra‑widefield cameras), pharmacology (anti‑VEGF drugs), and tele‑ophthalmology, expanding access to care through remote retinal grading. Economically, preventing vision loss reduces disability costs, preserves quality of life, and maintains workforce productivity.From a research perspective, DR serves as a model for studying microvascular pathology, inflammation, and angiogenesis, informing therapies for other retinal diseases such as age‑related macular degeneration. Public‑health campaigns emphasizing blood‑sugar control, blood‑pressure management, and regular eye exams have measurable impact on reducing DR incidence, underscoring the importance of interdisciplinary care between endocrinologists, primary‑care physicians, and eye specialists.
